Volume 10,Issue 3
Pathophysiology and Drugs for Hyperadrenocorticism
Cushing’s syndrome (CS) is one of the most common endocrine disorders in dogs, with systemic signs caused by excessive corticosteroid (mainly cortisol) secretion from the adrenal glands. Drugs commonly used in veterinary medicine, drugs whose usefulness has been reported in case reports, and drugs used in human medicine are also introduced.
1. Bennaim M, Shiel RE, Mooney CT. Diagnosis of Spontaneous Hyperadrenocorticism in Dogs. Part 1: Pathophysiology, Aetiology, Clinical and Clinicopathological Features. Vet J. 2019;252:105342.
2. Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing’s Syndrome: State of the Art. Lancet Diabetes Endocrinol. 2016;4(7):611–619.
3. Behrend EN. Hyperadrenocorticism. In: Canine and Feline Endocrinology. 4th ed. Elsevier Inc., Netherlands; 2015. pp. 377–451.
4. Park FM, Blois SL, Abrams-Ogg AC, et al. Hypercoagulability and ACTH-dependent Hyperadrenocorticism in Dogs. J Vet Intern Med. 2013;27(5):1136–1142.
5. San José PG, Bermejo CA, Moral IC, et al. Prevalence and Risk Factors Associated With Systemic Hypertension in Dogs With Spontaneous Hyperadrenocorticism. J Vet Intern Med. 2020;34(5):1768–1778.
6. Notari L, Burman O, Mills D. Behavioural Changes in Dogs Treated With Corticosteroids. Physiol Behav. 2015;151:609–616.
7. Sanders K, Kooistra HS, Galac S. Treating Canine Cushing’s Syndrome: Current Options and Future Prospects. Vet J. 2018;241:42–51.
8. Nam S, Kim T-W, Song K-H, et al. Evaluation of Compounded Trilostane Packets for Dogs With Naturally Occurring Hyperadrenocorticism. J Vet Intern Med. 2021;35(4):1729–1732.
9. Shirley M. Ketoconazole in Cushingʼs Syndrome: A Profile of Its Use. Drugs & Therapy Perspectives. 2021;37:55–64.
10. Lien Y-H, Huang H-P. Use of Ketoconazole to Treat Dogs With Pituitary-Dependent Hyperadrenocorticism: 48 Cases (1994-2007). J Am Vet Med Assoc. 2008;233(12):1896–1901.
11. Moore LE, Biller DS, Olsen DE. Hyperadrenocorticism Treated With Metyrapone Followed by Bilateral Adrenalectomy in a Cat. J Am Vet Med Assoc. 2000;217(5):691–694.
12. Castillo VA, Gómez NV, Lalia JC, et al. Cushingʼs Disease in Dogs: Cabergoline Treatment. Res Vet Sci. 2007;85(1):26–34.
13. Bruyette DS, Ruehl WW, Entriken T, et al. Management of Canine Pituitary-Dependent Hyperadrenocorticism With L-Deprenyl (Anipryl). Vet Clin North Am Small Anim Pract. 1997;27(2):273–286.
14. Reusch CE, Steffen T, Hoerauf A. The Efficacy of L-Deprenyl in Dogs With Pituitary-Dependent Hyperadrenocorticism. J Vet Intern Med. 1999;13(4):291–301.
15. Braddock JA, Church DB, Robertson ID, et al. Inefficacy of Selegiline in Treatment of Canine Pituitary Dependent Hyperadrenocorticism. Aust Vet J. 2004;82(5):272–277.
16. Castinetti F, Fassnacht M, Johanssen S, et al. Merits and Pitfalls of Mifepristone in Cushing’s Syndrome. Eur J Endocrinol. 2009;160(6):1003–1010.
17. Lottati M, Bruyette DS. Outcomes of the Addition of Pasireotide to Traditional Adrenal-Directed Treatment for Dogs With Pituitary-Dependent Hyperadrenocorticism Secondary to Macroadenoma: 9 Cases (2013-2015). J Am Vet Med Assoc. 2018;252(11):1403–1408.